Bioline Rx Ltd ADR (NASDAQ:BLRX) does about 732.47K shares in volume on a normal day but saw 783630 shares change hands in the recent trading day. The company now has a market cap of 25.28M USD. Its current market price is $0.30, marking an increase of 3.48% compared to the previous close of $0.29. The 52 week high reached by this stock is $1.89 whilst the lowest price level in 52 weeks is $0.25.
Bioline Rx Ltd ADR (BLRX) has a 20-day trading average at $0.4092 and the current price is -84.29% off the 52-week high compared with 18.80% distance from its 52-week low. The 50-day simple moving average of the closing price is $0.4623 and its 200-day simple moving average is $0.7069. If we look at the stock’s price movements over the week, volatility stands at 12.55%, which decreases to 10.44% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 33.85 to suggest the stock is neutral.
The consensus objective for the share price is $5.50, suggesting that the stock has a potential upside of 94.55% over the period.
FactSet Research has provided data showing that 1 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 0 advise that it is a overweight. 1 analysts have rated it as a buy and 0 have advised that investors hold their positions. The consensus recommendation rating is Buy and Wall Street’s advice is for investors to Strong Buy the stock.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on May 18, 2017 when Maxim Group upgraded the stock to “Buy” and issued a price target of between $1 and $3. Maxim Group downgraded its price target at $4-$1.
The current price level is -27.43%, -35.76%, and -57.99% away from its SMA20, SMA50, and SMA200 respectively, with the BLRX price moving above the 50-day SMA on current market day. Bioline Rx Ltd ADR (BLRX) stock is down -8.12% over the week and -30.75% over the past month. Its price is -81.08% year-to-date and -79.38% over the past year.
To reach the target analysts have set, the stock logically needs to grow 94.55 percent from here.
The company has a return on investment of -71.70% and return on equity of -184.09%. The beta has a value of 1.40. Price to book ratio is 2.79 and price to sales ratio is 1.15.
